Laura Rogers
Allergy · Chicago, ILNPI 1639154156
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 224 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,720 and has fallen 99.0% since, to $17 in 2025.
Across 224 payments — averaging $27.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$981
- Amgen$667
- Regeneron Healthcare Solutions, Inc.$545
- Pfizer$431
- Sanofi$416
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,189100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $1,049 |
| GSK | 45 | $981 |
| Amgen | 7 | $667 |
| Regeneron Healthcare Solutions, Inc. | 15 | $545 |
| Pfizer | 15 | $431 |
| Sanofi | 15 | $416 |
| Optinose US, Inc. | 23 | $369 |
| Novartis | 17 | $308 |
| Boehringer Ingelheim | 7 | $207 |
| Genentech USA, Inc. | 3 | $160 |
| Kaleo, Inc. | 8 | $156 |
| Greer Laboratories, Inc. | 9 | $155 |
| Teva Pharmaceuticals USA, Inc. | 5 | $124 |
| Hospira, Inc. | 5 | $104 |
| Shire North American Group Inc | 4 | $83 |
| Alk-abello, Inc | 4 | $80 |
| Octapharma USA, Inc. | 3 | $73 |
| Tris Pharma Inc | 4 | $64 |
| LEO Pharma Inc. | 3 | $54 |
| Genentech, Inc. | 2 | $43 |
| Phadia US Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Mission Pharmacal Company | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,202 in reported general payments places this provider in the 70th percentile of 47 allergy providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,813 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $981 | $4,81312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 47 allergy providers in Illinois.
Other allergy in Chicago
- Brian RotskoffChicago$82K
- Bruce BochnerChicago$43K
- Alex ThomasChicago$9K
- Fei Li KuangChicago$3K
- Edward LisbergChicago$3K
- Melissa WattsChicago$2K
- Anne DittoChicago$2K
- Grant EdlandChicago$1K
- Michael RosenbergChicago$712
- Rayna SchwartzChicago$150
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.